<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04644016</url>
  </required_header>
  <id_info>
    <org_study_id>20-480</org_study_id>
    <nct_id>NCT04644016</nct_id>
  </id_info>
  <brief_title>Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders</brief_title>
  <official_title>Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm study to investigate 1-year treatment related mortality (TRM) in&#xD;
      patients with life threatening non-malignant and malignant hematologic disorders who do not&#xD;
      have a matched related donor for allogeneic transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">December 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related mortality at 1 year after myeloablative cord transplant</measure>
    <time_frame>1 year</time_frame>
    <description>The primary objective of this study is to assess treatment related mortality (TRM) at 1 year after myeloablative cord transplant.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>AML</condition>
  <condition>ALL</condition>
  <condition>MDS</condition>
  <condition>MPD Withou Myelofibrosis</condition>
  <condition>NHL or HL</condition>
  <condition>Inherited Metabolic Disorders</condition>
  <condition>Hemoglobinopathies</condition>
  <condition>Bone Marrow Failure</condition>
  <condition>HLH</condition>
  <arm_group>
    <arm_group_label>Participants with non-malignant and malignant hematologic disorders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Clofarabine 30 mg/m2</description>
    <arm_group_label>Participants with non-malignant and malignant hematologic disorders</arm_group_label>
    <other_name>Clolar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 10 mg/m2</description>
    <arm_group_label>Participants with non-malignant and malignant hematologic disorders</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan per PK</description>
    <arm_group_label>Participants with non-malignant and malignant hematologic disorders</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine-A</intervention_name>
    <description>GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.</description>
    <arm_group_label>Participants with non-malignant and malignant hematologic disorders</arm_group_label>
    <other_name>CSA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.</description>
    <arm_group_label>Participants with non-malignant and malignant hematologic disorders</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cord Blood Graft</intervention_name>
    <description>The CB graft will be infused on day 0 per standard practice</description>
    <arm_group_label>Participants with non-malignant and malignant hematologic disorders</arm_group_label>
    <other_name>CB graft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participant Inclusion Criteria:&#xD;
&#xD;
        Age and Donor Status:&#xD;
&#xD;
        Patients with age ≤ 21 years at time of consent with no available and suitably matched&#xD;
        related or unrelated donor in the required time period.&#xD;
&#xD;
        Diagnoses :&#xD;
&#xD;
        I. Acute myelogenous leukemia (AML) :&#xD;
&#xD;
          -  Complete first remission (CR1) at high risk for relapse such as any of the following:&#xD;
&#xD;
               -  Known prior diagnosis of myelodysplasia (MDS) or myeloproliferative disorder&#xD;
                  (MPS).&#xD;
&#xD;
               -  Therapy-related AML (t-AML).&#xD;
&#xD;
               -  White cell count at presentation &gt; 100,000.&#xD;
&#xD;
               -  Presence of extramedullary leukemia at diagnosis.&#xD;
&#xD;
               -  Any unfavorable subtype by FAB or WHO classification.&#xD;
&#xD;
               -  High-risk cytogenetics (e.g. those associated with MDS, abnormalities of 5, 7, 8,&#xD;
                  complex karyotype) or high-risk molecular abnormalities.&#xD;
&#xD;
               -  Requirement for 2 or more inductions to achieve CR1.&#xD;
&#xD;
               -  Presence of Minimal Residual Disease (MRD+) by cytogenetics, flow cytometry or&#xD;
                  molecular methods after induction.&#xD;
&#xD;
               -  Any patient with newly diagnosed AML with intermediate risk cytogenetics who&#xD;
                  elects allograft with curative intent over consolidation chemotherapy.&#xD;
&#xD;
               -  Any patient unable to tolerate consolidation chemotherapy as would have been&#xD;
                  deemed appropriate by the treating physician.&#xD;
&#xD;
               -  Other high-risk features not defined above.&#xD;
&#xD;
          -  Complete second remission (CR2).&#xD;
&#xD;
          -  Primary refractory or relapsed AML with less than 10% blasts by bone marrow&#xD;
             morphology. Patients with cytogenetic, flow cytometric, or molecular abnormalities in&#xD;
             ≤ 10% of cells are eligible.&#xD;
&#xD;
        II. Acute lymphoblastic leukemia (ALL):&#xD;
&#xD;
          -  Complete first remission (CR1) at high risk for relapse such as any of the following:&#xD;
&#xD;
               -  White cell count at presentation &gt; 30,000 for B-cell lineage and &gt; 100,000 for&#xD;
                  T-cell lineage.&#xD;
&#xD;
               -  Presence of any high-risk cytogenetic abnormalities such as t (9;22), t (1;19), t&#xD;
                  (4;11) or other MLL rearrangements (11q23) or other high-risk molecular&#xD;
                  abnormality.&#xD;
&#xD;
               -  Failure to achieve complete remission (CR) after four weeks of induction therapy.&#xD;
&#xD;
               -  Persistence or recurrence of MRD on therapy.&#xD;
&#xD;
               -  Any patient unable to tolerate consolidation and/or maintenance chemotherapy as&#xD;
                  would have been deemed appropriate by the treating physician.&#xD;
&#xD;
               -  Other high-risk features not defined above.&#xD;
&#xD;
          -  Complete second remission (CR2).&#xD;
&#xD;
          -  Primary refractory or relapsed ALL with MRD disease after antibody therapy (e.g.,&#xD;
             blinatumomab, inotuzumab, other) and/or CAR-T cell therapy.&#xD;
&#xD;
        III. Other acute leukemias:&#xD;
&#xD;
        Leukemias of ambiguous lineage or of other types (e.g. blastic plasmacytoid dendritic cell&#xD;
        neoplasm) with less than 5% blasts by BM morphology. Patients with persistent/relapsed&#xD;
        disease with cytogenetic, flow cytometric or molecular aberrations in ≤ 5% of cells are&#xD;
        eligible.&#xD;
&#xD;
        IV. Myelodysplastic Syndrome (MDS) / Myeloproliferative Disorders (MPD) other than&#xD;
        myelofibrosis:&#xD;
&#xD;
          -  International prognostic scoring system (IPSS) risk score of INT-2 or high risk at the&#xD;
             time of diagnosis.&#xD;
&#xD;
          -  Any IPSS risk category if life-threatening cytopenia(s) exists.&#xD;
&#xD;
          -  Any IPSS risk category with karyotype or genomic changes that indicate high risk for&#xD;
             progression to acute myelogenous leukemia.&#xD;
&#xD;
          -  MDS/ myeloproliferative disorder overlap syndromes without myelofibrosis.&#xD;
&#xD;
          -  MDS/ MPD patients must have less than 10% bone marrow myeloblasts and ANC ≥ 0.2&#xD;
             (growth factor supported if necessary) at transplant work-up.&#xD;
&#xD;
        V. Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) at high-risk of relapse or&#xD;
        progression if not in remission:&#xD;
&#xD;
          -  Eligible patients with aggressive histology (such as, but not limited to, diffuse&#xD;
             large B-cell NHL, mantle cell NHL, and T-cell histology) in CR.&#xD;
&#xD;
          -  Eligible patients with indolent B cell NHL (such as, but not limited to, follicular,&#xD;
             small cell or marginal zone NHL) will have 2nd or subsequent progression with stable&#xD;
             disease/ CR/ PR with no single lesion equal to or more than 5 cm.&#xD;
&#xD;
          -  Eligible patients with HL will be those without progression of disease (POD) after&#xD;
             salvage chemotherapy with no single lesion ≥ 5 cm.&#xD;
&#xD;
        VI. Inherited Metabolic Disorders [also see EBMT Handbook for discussion on patient&#xD;
        eligibility for allogeneic transplant; in general, patients are considered early in the&#xD;
        disease course, before they develop neurologic symptoms (46)]:&#xD;
&#xD;
          -  Hurler Syndrome&#xD;
&#xD;
          -  Hunter (MPS 2 - early disease)&#xD;
&#xD;
          -  Sly syndrome (MPSVIII)&#xD;
&#xD;
          -  α-Mannosidosis&#xD;
&#xD;
          -  X- ALD&#xD;
&#xD;
          -  Osteopetrosis&#xD;
&#xD;
          -  Metachromatic Leukodystrophy&#xD;
&#xD;
          -  Globoid (GLD)&#xD;
&#xD;
        VII. Non-Malignant disorders (other) [also see EBMT Handbook for criteria for transplant&#xD;
        (46)]&#xD;
&#xD;
          -  Hemoglobinopathies&#xD;
&#xD;
          -  Bone Marrow Failure syndromes&#xD;
&#xD;
          -  Immunodeficiencies, including HLH&#xD;
&#xD;
        Organ Function and Performance Status Criteria:&#xD;
&#xD;
          -  Karnofsky or Lansky score ≥ 70% (see Appendix)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL (unless benign congenital hyperbilirubinemia).&#xD;
&#xD;
          -  ALT ≤ 3 x upper limit of normal.&#xD;
&#xD;
          -  Pulmonary function (spirometry and corrected DLCO) ≥ 50% predicted (corrected for&#xD;
             hemoglobin) .&#xD;
&#xD;
          -  Left ventricular ejection fraction ≥ 50%.&#xD;
&#xD;
          -  Age-adjusted Hematopoietic Cell Transplantation-Comorbidity Index (aaHCT-CI) less than&#xD;
             or equal to 7.&#xD;
&#xD;
          -  Renal: serum creatinine ≤ 1.5x normal for age. If serum creatinine is outside the&#xD;
             normal range, then CrCl &gt; 50 mL/min/1.73m2 (calculated or estimated) or GFR&#xD;
             (mL/min/1.72m2) &gt;30% of predicted normal for age.&#xD;
&#xD;
        Normal GFR in Children and Young Adults (Age) : Mean GFR +- SD (mL/min/1.73 m2)&#xD;
&#xD;
        1 week: 40.6 + / - 14.8 2-8 weeks: 65.8 + / - 24.8 &gt;8 weeks: 95.7 + / - 21.7 2-12 years:&#xD;
        133.0 + / - 27.0 13-21 years (males): 140.0 + / - 30.0 13-21 years (females: 126.0 + / -&#xD;
        22.0&#xD;
&#xD;
        GFR, glomerular filtration rate; SD, standard deviation greater than 2 years old: Normal&#xD;
        GFR is 100 mL/ min. Infants: GFR must be corrected for body surf ace area.&#xD;
&#xD;
        For metabolic diseases: disease status to be evaluated according to EBMT Handbook [45].&#xD;
&#xD;
        Graft Criteria&#xD;
&#xD;
        CB units will be selected according to the current MSKCC unit selection algorithm. High&#xD;
        resolution 8 allele HLA typing and recipient HLA antibody profile will be performed. Cord&#xD;
        unit selection will occur based on HLA-match, total nucleated cell (TNC) and CD34+ cell&#xD;
        dose adjusted per patient body weight. The cord bank of origin will also be considered.&#xD;
        Donor specific HLA antibodies, if present, will also be taken into consideration and may&#xD;
        influence the selection of the graft. CB graft will consist of one or two CB units (CBU)&#xD;
        based on MSKCC selection algorithm.&#xD;
&#xD;
          -  Each CB unit must be at least 3/8 HLA-matched to the patient considering&#xD;
             high-resolution 8-allele HLA typing.&#xD;
&#xD;
          -  For malignant diseases follow MSKCC CBU selection algorithm&#xD;
&#xD;
          -  For non-malignant diseases, CBU will be required to have &gt; 5 x 107 TNC/kg; high HLA&#xD;
             allele level match is preferable&#xD;
&#xD;
        Participant Exclusion Criteria:&#xD;
&#xD;
          -  Inadequate performance status/ organ function.&#xD;
&#xD;
          -  Advanced metabolic disease (EBMT handbook).&#xD;
&#xD;
          -  Active CNS leukemic involvement.&#xD;
&#xD;
          -  Indolent NHL or Hodgkin lymphoma with progression of disease after most recent salvage&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Diagnosis of myelofibrosis or other malignancy with moderate-severe bone marrow&#xD;
             fibrosis.&#xD;
&#xD;
          -  Autologous stem cell transplant within the preceding 6 months.&#xD;
&#xD;
          -  Any prior allogeneic stem cell transplant.&#xD;
&#xD;
          -  Active and uncontrolled infection (bacterial/fungal/viral) at time of transplantation.&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Seropositivity for HTLV-1.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Patient or guardian unable to give informed consent or unable to comply with the&#xD;
             treatment protocol including appropriate supportive care, long-term follow-up, and&#xD;
             research tests.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Cancio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria I Cancio, MD</last_name>
    <phone>212-639-2446</phone>
    <email>canciom@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaap Jan Boelens, MD, PhD</last_name>
    <phone>212-639-3643</phone>
    <email>boelensj@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cancio, MD</last_name>
      <phone>212-639-2446</phone>
    </contact>
    <contact_backup>
      <last_name>E.</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute myelogenous leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Myelodysplasia</keyword>
  <keyword>MDS</keyword>
  <keyword>Myeloproliferative Disorder</keyword>
  <keyword>Therapy-Related AML and MDS</keyword>
  <keyword>Therapy-Related Acute Myeloid Leukemia</keyword>
  <keyword>T-AML</keyword>
  <keyword>High-risk cytogenetics</keyword>
  <keyword>Cord Blood Transplantation</keyword>
  <keyword>20-480</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Bone Marrow Failure Disorders</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

